Docetaxel administered every two weeks as second-line chemotherapy for advanced non-small cell lung cancer: A phase II study

Anticancer Research

Volumn 25, Issue 6 C, 2005, Pages 4713-4717

  De Petris, Luigi ^a   Migliorino, Maria Rita ^a   Ceribelli, Anna ^b   Martelli, Olga ^a   Di Molfetta, Michele ^a   Mancuso, Andrea ^a   De Santis, Stefano ^a   Di Salvia, Roberto ^a   De Marinis, Filippo ^a,c  

^a 5th Pneumo Oncology Unit   (Italy)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^c FoRO (Fondazione per la Ricerca Oncologica)   (Italy)

Author keywords

Docetaxel; Non small cell lung cancer

Indexed keywords

CISPLATIN; DOCETAXEL; GEFITINIB; GEMCITABINE; NAVELBINE;

ADULT; AGED; ANEMIA; ARTICLE; ASTHENIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; DIARRHEA; DISEASE COURSE; DOSE TIME EFFECT RELATION; DRUG EFFICACY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HICCUP; HUMAN; LUNG NON SMALL CELL CANCER; MALE; MUCOSA INFLAMMATION; NAIL DISEASE; NEUROPATHY; NEUTROPENIA; PARESTHESIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENT CANCER; SURVIVAL RATE; SURVIVAL TIME;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; TAXOIDS;

EID: 28444435808     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Pfister DG, Johnson DH, Azzoli CG, Sause W, Smith TJ, Baker S Jr, Olak J, Stover D, Strawn JR, Turrisi AT and Somerfield MR: American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 22: 330-353, 2004.
2. Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O'Rourke M, Levitan N, Gressot L, Vincent M, Burkes R, Coughlin S, Kim Y and Berille J: Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18: 2095-2103, 2000.
3. Fossella FV, DeVore R, Kerr RN, Crawford J, Natale RR, Dunphy F, Kalman L, Miller V, Lee JS, Moore M, Gandara D, Karp D, Vokes E, Kris M, Kim Y, Gamza F and Hammershaimb L: Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 18: 2354-2362, 2000.
4. Fossella FV, Lee JS, Shin DM, Calayag M, Huber M, Perez-Soler R, Murphy WK, Lippman S, Benner S, Glisson B, Chasen M, Hong WK and Raber M: Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer. J Clin Oncol 13: 645-651, 1995.
5. Gandara DR, Vokes E, Green M, Bonomi P, Devore R, Comis R, Carbone D, Karp D and Belani C: Activity of docetaxel in platinum-treated non-small-cell lung cancer: results of a phase II multicenter trial. J Clin Oncol 18: 131-135, 2000.
6. Gridelli C, Frontini L, Barletta E, Rossi A, Barzelloni ML, Scognamiglio F, Guida C, Gatani T, Fiore F, De Bellis M, Marfella A and Manzione L: Single agent docetaxel plus granulocyte-colony stimulating factor (G-CSF) in previously treated patients with advanced non-small cell lung cancer. A phase II study and review of the literature. Anticancer Res 20: 1077-1084, 2000.
7. Mattson K, Bosquee L, Dabouis G, Le Groumellec A, Pujol JL, Marien S, Stupp R, Douillard JY, Bragas B, Berille J, Olivares R and Le Chevalier T: Phase II study of docetaxel in the treatment of patients with advanced non-small cell lung cancer in routine daily practice. Lung Cancer 29: 205-216, 2000.
8. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC and Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216, 2000.
9. Arbuck SG, McClure J, Ivy SP and Setser A: The Common Toxicity Criteria Manual. CTEP Website, http://ctep.info.nih.gov.
10. Simon R: Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10: 1-10, 1989.
11. Kaplan EL and Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 55: 457-481, 1958.
12. Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, Gatzemeier U, Tsao TC, Pless M, Muller T, Lim HL, Desch C, Szondy K, Gervais R, Shaharyar, Manegold C, Paul S, Paoletti P, Einhorn L and Bunn PA Jr: Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22: 1589-1597, 2004.
13. Gridelli C, Gallo C, Di Maio M, Barletta E, Illiano A, Maione P, Salvagni S, Piantedosi FV, Palazzolo G, Caffo O, Ceribelli A, Falcone A, Mazzanti P, Brancaccio L, Capuano MA, Isa L, Barbera S and Perrone F: A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 study. Br J Cancer 91: 1996-2004, 2004.
14. 2) as second-line monotherapy for non-small-cell lung cancer. Ann Oncol 15: 38-44, 2004.
15. Gervais R, Ducolone A, Breton JL, Braun D, Lebeau B, Vaylet F, Debieuvre D, Pujol JL, Tredaniel J, Clouet P and Quoix E: Phase II randomised trial comparing docetaxel given every 3 weeks with weekly schedule as second-line therapy in patients with advanced non-small-cell lung cancer (NSCLC). Ann Oncol 16: 90-96, 2005.
16. Vazquez S, Grande C, Amenedo M, Firvida JL, Lazaro M, Alonso G, Curiel T, Huidobro G, Mel JR and Ramos M: Biweekly docetaxel as second-line chemotherapy of patients with advanced non-small cell lung cancer: a phase II study of the Galician Lung Cancer Group (GGCP 006-00). Anticancer Drugs 15: 489-494, 2004.
17. Camps C, Massuti B, Jimenez AM, Maestu I, Almenar D, Garcia R, Gonzalez-Iarriba JL, Vinolas N, Garcia C and Rosell R: Two second-line docetaxel dose-schedules in advanced non-small cell lung cancer (NSCLC): a Spanish Lung Cancer Group (SLCG) phase III trial. Lung Cancer 41(suppl 2): Abstr O-2, 2003.
18. Schuette W, Nagel S, Serke M, Lautenschlaeger C, Hans K and Lorenz C: Second-line chemotherapy for advanced non-small cell lung cancer (NSCLC) with weekly versus three-weekly docetaxel: results of a randomized phase III study. J Clin Oncol, 2004 ASCO Annual Meeting Proceedings 22: Abstr 7036, 2004.